11/20
07:17 am
eprx
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months [Yahoo! Finance]
High
Report
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months [Yahoo! Finance]
11/20
07:09 am
eprx
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months [Globe and Mail, The (Toronto, Canada)]
High
Report
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months [Globe and Mail, The (Toronto, Canada)]
11/20
07:00 am
eprx
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
High
Report
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
11/15
06:00 am
eprx
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Medium
Report
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
11/14
05:27 pm
eprx
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting [Yahoo! Finance]
11/14
05:00 pm
eprx
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Medium
Report
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
11/14
07:35 am
eprx
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $9.00 price target on the stock.
Low
Report
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $9.00 price target on the stock.
11/13
05:08 pm
eprx
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 [Globe and Mail, The (Toronto, Canada)]
Low
Report
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 [Globe and Mail, The (Toronto, Canada)]
11/13
05:00 pm
eprx
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Low
Report
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
11/12
06:11 pm
eprx
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]
Medium
Report
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]
11/12
05:58 pm
eprx
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Globe and Mail, The (Toronto, Canada)]
11/12
05:56 pm
eprx
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Medium
Report
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
11/7
05:00 pm
eprx
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Low
Report
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
11/1
06:59 pm
eprx
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 [Yahoo! Finance Canada]
High
Report
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 [Yahoo! Finance Canada]
10/31
07:39 pm
eprx
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million [Yahoo! Finance]
High
Report
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million [Yahoo! Finance]
10/31
07:36 pm
eprx
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
High
Report
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
10/28
07:00 am
eprx
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Low
Report
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
10/15
07:00 am
eprx
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Medium
Report
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
10/10
07:00 am
eprx
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Neutral
Report
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
10/2
05:14 pm
eprx
Eupraxia Pharmaceuticals Strengthens Senior Management Team [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Strengthens Senior Management Team [Yahoo! Finance]
10/2
05:01 pm
eprx
Eupraxia Pharmaceuticals Strengthens Senior Management Team
Low
Report
Eupraxia Pharmaceuticals Strengthens Senior Management Team